Can Chlorthalidone Be Prescribed with GFR 47/Cr 1.5?
Yes, chlorthalidone can be prescribed at a GFR of 47 mL/min/1.73 m², but you must proceed with caution and close monitoring given the proximity to the eGFR threshold of 45 mL/min/1.73 m² recommended in current guidelines.
Guideline-Based Threshold
The 2025 ACC/AHA hypertension guidelines specifically recommend thiazide-like diuretics (chlorthalidone or indapamide) as part of first-line therapy for resistant hypertension in patients with eGFR ≥45 mL/min/1.73 m² 1. Your patient at GFR 47 technically meets this threshold, though marginally.
Evidence Supporting Use at This Level
The landmark CLICK trial (2021) demonstrated that chlorthalidone is effective and can be used in patients with stage 4 CKD (mean eGFR 23.2 mL/min/1.73 m²), showing a 10.5 mm Hg reduction in 24-hour systolic blood pressure compared to placebo 2. This provides strong evidence that chlorthalidone works even at much lower kidney function than your patient has.
- In the resistant hypertension subgroup of CLICK, chlorthalidone reduced systolic BP by 13.9 mm Hg 3
- Earlier pilot studies confirmed BP reduction in patients with eGFR 20-45 mL/min/1.73 m² 4
- An 8-week study showed no difference in efficacy between patients with eGFR <60 vs ≥60 mL/min/1.73 m² 5
Practical Prescribing Algorithm
Starting dose: Begin with 12.5 mg daily (not 25 mg) given the reduced kidney function
Titration schedule:
- Increase to 25 mg after 4 weeks if BP remains uncontrolled and no adverse effects
- Maximum dose 50 mg daily if needed 2
Monitoring requirements (critical at this GFR level):
- Check serum potassium, creatinine, and sodium at weeks 1-2, then week 4, then every 4 weeks during titration
- Monitor for orthostatic hypotension, especially if on loop diuretics
- Check uric acid and glucose periodically
Key Safety Concerns
The FDA label warns to "use with caution in severe renal disease" and notes that chlorthalidone "may precipitate azotemia" 6. However, this refers primarily to more advanced disease than your patient has.
Common adverse effects to monitor:
- Hypokalemia (most common - occurred in 4 patients in one study) 4
- Reversible creatinine elevation (expect 10-20% increase, typically peaks at 8 weeks) 4, 2
- Hyperuricemia
- Hyponatremia
- Hyperglycemia
- Dizziness/orthostatic hypotension
Critical pitfall: If the patient is already on a loop diuretic, the risk of electrolyte disturbances increases substantially. In the CLICK trial, 60% were on loop diuretics, and adverse events were more frequent in this subgroup 2, 3.
When to Withhold or Discontinue
Per FDA labeling: "If progressive renal impairment becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy" 6.
Specific thresholds for concern:
- Creatinine increase >30% from baseline
- Potassium <3.0 mEq/L despite supplementation
- Sodium <130 mEq/L
- Symptomatic orthostatic hypotension
Clinical Context Matters
If this patient has resistant hypertension (uncontrolled on 3+ medications including a diuretic), chlorthalidone becomes even more compelling. The 2025 guidelines recommend adding a mineralocorticoid receptor antagonist (MRA) like spironolactone at eGFR ≥45 1, but chlorthalidone offers an alternative with lower hyperkalemia risk and can even enable safer concurrent MRA use 7.
Bottom line: At GFR 47, you are within guideline-supported territory for chlorthalidone use, backed by robust trial evidence showing efficacy at much lower GFR levels. Start low (12.5 mg), monitor closely (especially weeks 1-4), and titrate based on response and tolerability.